Amid desperate efforts to find a treatment for the neurodegenerative disease Alzheimer’s, the aducanumab saga continues, as a US Food and Drug Administration panel will determine whether a post-hoc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback